Wealth Management

Bond funds delivered modest results last year, with the average fund returning 4.8%, though nearly all finished in positive territory. Surprisingly, high-yield and emerging-market bond funds dominated the top performers, buoyed by strong global growth and favorable currency trends despite an inverted yield curve. 

 

Their outperformance suggests a speculative tone in markets, as riskier assets typically lag when investors grow cautious about the economy. However, higher volatility weighed on their ratings, leaving most of the top 20 funds with only “hold” grades, except for Delaware Pooled Trust High-Yield, which earned a B-minus.

 

In contrast, lagging funds saw declines in principal value, weak dividend payments, and overall “sell” ratings, with inflation-protected funds failing to meet expectations. 


Finsum: The divide highlights how chasing yield in riskier segments delivered gains last year, while traditionally safer strategies struggled to keep up.

 

Small cap growth stocks have rallied sharply since April 8, with the Russell 2000 Growth Index up 34.2%, but large cap growth stocks still outpaced them with a 40.5% gain over the same period. Over the past decade, small growth stocks have significantly lagged large growth, delivering less than half the return. 

 

Research shows that active management has historically outperformed the Russell 2000 Growth Index, though recent rebounds have favored the passive benchmark as high-beta and unprofitable companies surged. 

 

Sector and industry standouts in small growth include materials, industrials, technology, and niche firms such as Credo Technology and Joby Aviation, with many of the highest returns concentrated in the most volatile stocks. Active small cap growth funds typically avoid the riskiest and least profitable names, which hurt short-term performance but aligns with evidence that profitable small caps outperform over time. 


Finsum: Active strategies may still offer investors a more resilient path within small growth equities despite the recent rally.

High-yield dividend opportunities are harder to find in today’s market, but Realty Income, Healthpeak Properties, and Pfizer all stand out with payouts above 5%. 

  1. Realty Income, a net lease REIT, offers a 5.5% yield and decades of consistent growth, supported by a vast property portfolio and international expansion potential. 
  2. Healthpeak Properties, which merged with Physicians Realty last year, now provides a 6.8% yield as demand for lab space stabilizes and medical office buildings strengthen its base.
  3. Pfizer shares have fallen about 60% since their pandemic peak, but the company has raised its dividend for 16 consecutive years and now yields 6.9%. While looming patent cliffs pose risks, Pfizer has invested heavily in acquisitions that could add $20 billion in annual sales by 2030. 

Finsum: Collectively, these three dividend payers offer compelling income opportunities with the potential for steady long-term growth.

Page 15 of 375

Contact Us

Newsletter

Subscribe

Subscribe to our daily newsletter

Top